303.70 3.25 (1.08%)
NSEJan 27, 2021 03:09 PM
Latest broker research reports with buy, sell, hold recommendations along with forecast target prices and upside. Browse thousands of reports and search by company or the broker.
|Summary||Date||Stock||Broker||Price at Reco.||Target||Price at reco|
Change since reco(%)
|2019-11-11||FDC Ltd. +||Rudra Shares and Stock Brokers Ltd||180.50||220.00||180.50 (68.25%)||Target met||Buy|
Rudra Shares and Stock Brokers Ltd
Forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmic & First in South East Asia to offer ophthalmic formulations, using Blow-Fill-Seal (BFS) technology. FDC is a fundamentally strong company with huge cash in its balance sheet. The company has good product profile starting with Electral which is the market leader in the ORS segment. Moreover, company continues to report decent operating margins and generates sufficient free cash flow from operations every year where part has been used for buyback in the past, for...
|2018-08-07||FDC Ltd. +||ICICI Securities Limited||244.00||325.00||244.00 (24.47%)||Buy|
|2017-08-21||FDC Ltd. +||Choice India||170.25||205.00||170.25 (78.38%)||Target met||Buy|
FDC Limited (Food, Drugs and Chemicals) is a fully integrated pharmaceutical company which has been in business for more than 70 years. The company is engaged in manufacturing of specialized formulations and oral rehydration salts (ORS) since 1972. The company is currently ranked 26th in India as per AWACS-AIOCD, recording a growth of 3.7% and attaining a market share of 0.89% whereas IPM (Indian Pharmaceutical markets) recorded a growth of 10.3% as per secondary sales, as of March 2017. The Company has built a visible presence across markets in Europe, USA, Asia, Africa, Latin America and Confederation of Independent States (CIS). It has...
|2016-12-05||FDC Ltd. +||HDFC Securities||223.30||255.00||223.30 (36.01%)||Buy|
|2013-12-31||FDC Ltd. +||Ashika Research||129.40||170.00||129.40 (134.70%)||Target met||Buy|